Aytu BioPharma (NASDAQ: AYTU) is a dynamic specialty pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on ADHD and other common conditions. Our evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As we continue on this trajectory, we continue to evaluate novel therapeutics to in-license or acquire.
Location: United States, Colorado
Investors 1
| Date | Name | Website |
| 07.05.2025 | Johns Hopk... | ventures.j... |
Mentions in press and media 7
| Date | Title | Description |
| 05.01.2023 | Aytu BioPharma Announces 1-for-20 Reverse Stock Split | ENGLEWOOD, CO / ACCESSWIRE / January 5, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effec... |
| 15.08.2022 | Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering | ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the clos... |
| 08.08.2022 | Aytu BioPharma Announces Launch of Public Offering | ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launc... |
| 29.06.2022 | Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors | ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of ... |
| 13.06.2022 | Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference | ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Par... |
| 12.04.2021 | AYTU BIOPHARMA, INC. Aytu BioPharma : Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics | Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective ti... |
| 17.10.2016 | Sperm test 2.0: New diagnostics aim to better understand male infertility | PASADENA, Calif. — Traditional sperm tests don’t reveal much. They can assess how many sperm a man produces, whether sperm are misshapen, and how well they swim. But that’s about it. Determined to extract more data, several startups are dev... |